Results 1 to 10 of about 2,198,265 (159)

Best Practices in Nuclear Imaging for the Diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in KSA: The Eagle Eyes of Local Experts [PDF]

Diagnostics
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a complex and serious form of heart failure caused by the accumulation of transthyretin amyloid protein in the heart muscle. Variable symptoms of ATTR-CM can lead to a delayed diagnosis.
Abdullah Alqarni, Ahmed Aljizeeri, Aquib Mohammadidrees Bakhsh, Hossam Ahmed Maher El-Zeftawy, Hussein R. Farghaly, Mukhtar Ahmed M. Alqadhi, Mushref Algarni, Zain Mohammed Asiri, Ahmed Osman, Haya Haddadin, Islam Alayary, Mouaz H. Al-Mallah   +11 more
doaj   +3 more sources

Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups [PDF]

Orphanet Journal of Rare Diseases, 2021
Background Transthyretin amyloidosis, or ATTR, is a progressive and debilitating rare proteopathy generally manifested as either transthyretin amyloid polyneuropathy (ATTR-PN) or transthyretin amyloid cardiomyopathy (ATTR-CM).
David Rintell, Dena Heath, Florencia Braga Mendendez, Elizabeth Cross, Theodore Cross, Vincent Knobel, Bruno Gagnon, Cameron Turtle, Alan Cohen, Edward Kalmykov, Jonathan Fox   +10 more
doaj   +2 more sources

Quantitative Proteomics of Plasma-Derived Extracellular Vesicles Reveals a Plasminogen-Centered Protein Network in Transthyretin Cardiac Amyloidosis [PDF]

JACC: Advances
Background: The prognosis of patients with transthyretin cardiac amyloidosis (ATTR) remains poor; this is primarily due to late diagnosis, when irreversible damage has already occurred.
Amira Zaroui, MD, Damien Habert, MSc, Benoit Vallée, MSc, Mounira Kharoubi, PhD, Soraya Fellahi, PharmD, Benoit Vingert, PhD, Michel Seve, PharmD, PhD, Ilaria Cascone, PhD, Vincent Audard, MD, PhD, Emmanuel Itti, MD, PhD, Hajer Abroud, PharmD, Arnault Galat, MD, Thibaud Damy, MD, PhD, Sandrine Bourgoin-Voillard, PhD, Valérie Molinier-Frenkel, MD, PhD   +14 more
doaj   +2 more sources

Cardiac transplantation in transthyretin amyloid cardiomyopathy: Outcomes from three decades of tertiary center experience

Frontiers in Cardiovascular Medicine, 2023
AimsTransthyretin cardiac amyloidosis (ATTR-CM) is a progressive and fatal cardiomyopathy. Treatment options in patients with advanced ATTR-CM are limited to cardiac transplantation (CT).
Yousuf Razvi, Aldostefano Porcari, Aldostefano Porcari, Concetta Di Nora, Rishi K. Patel, Adam Ioannou, Muhammad U. Rauf, Ambra Masi, Steven Law, Liza Chacko, Tamer Rezk, Sriram Ravichandran, Janet Gilbertson, Dorota Rowczenio, Iona J. Blakeney, Nandita Kaza, David F. Hutt, Helen Lachmann, Ashutosh Wechalekar, William Moody, Sern Lim, Colin Chue, Carol Whelan, Lucia Venneri, Ana Martinez-Naharro, Marco Merlo, Gianfranco Sinagra, Ugolino Livi, Philip Hawkins, Marianna Fontana, Julian D. Gillmore   +30 more
doaj   +1 more source

Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an underdiagnosed cause of heart failure (HF) among patients ≥60 years of age. Although the V122I (valine to isoleucine substitution at position 122 of the transthyretin protein) variant ...
Avni Madhani, Natalia Sabogal, Daniel Massillon, Ludwine D. Paul, Carlos Rodriguez, Denise Fine, Stephen Helmke, Morgan Winburn, Damian Kurian, Farbod Raiszadeh, Sergio Teruya, Elizabeth Cohn, Andrew J. Einstein, Edward J. Miller, Lawreen H. Connors, Mathew S. Maurer, Frederick L. Ruberg   +16 more
doaj   +1 more source

Detection of transthyretin amyloid cardiomyopathy by automated data extraction from electronic health records

ESC Heart Failure, 2023
Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM), a progressive and fatal cardiomyopathy, is frequently misdiagnosed or entails diagnostic delays, hindering patients from timely treatment.
Ana Moya, Clara L. Oeste, Monika Beles, Sofie Verstreken, Riet Dierckx, Ward Heggermont, Jozef Bartunek, Eline Bogaerts, Imke Masuy, Dries Hens, Dario Bertolone, Marc Vanderheyden   +11 more
doaj   +1 more source

Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden

Open Heart, 2021
Objective Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, progressive and fatal condition caused by deposition of transthyretin amyloid fibrils in the heart.
J Gustav Smith, Finn Gustafsson, Johanna Kuusisto, Einar Gude, Rosa Elisabeth Lauppe, Johan Liseth Hansen, Christian Gerdesköld, Mark H Rozenbaum, Anne Mette Strand, Merja Vakevainen   +9 more
doaj   +1 more source

Healthcare resource use of patients with transthyretin amyloid cardiomyopathy

ESC Heart Failure, 2022
Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is the cardiac manifestation of transthyretin amyloidosis (ATTR). The aim of this study was to estimate healthcare resource use for ATTR‐CM patients compared with heart failure (HF) patients, in Denmark,
Rosa Lauppe, Johan Liseth Hansen, Anna Fornwall, Katarina Johansson, Mark H. Rozenbaum, Anne Mette Strand, Merja Vakevainen, Johanna Kuusisto, Einar Gude, J. Gustav Smith, Finn Gustafsson   +10 more
doaj   +1 more source

Assessment and Management of Older Patients With Transthyretin Amyloidosis Cardiomyopathy: Geriatric Cardiology, Frailty Assessment and Beyond

Frontiers in Cardiovascular Medicine, 2022
Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is commonly diagnosed in older adults, in particular the wild-type (ATTRwt), which is regarded as an age-related disease.
Biobelemoye Irabor, Jacqueline M. McMillan, Jacqueline M. McMillan, Nowell M. Fine, Nowell M. Fine   +4 more
doaj   +1 more source

Summation of Precordial R Wave Amplitudes, a Clinical Parameter for Detecting Early TTR Amyloidosis Cardiac Involvement

Journal of Cardiovascular Development and Disease, 2022
There have been several reports on the identification of the stage of transthyretin amyloid cardiomyopathy (ATTR-CM); however, a staging system for ATTR-CM has not yet been established.
Yoshitaka Isotani, Eisuke Amiya, Junichi Ishida, Issei Komuro   +3 more
doaj   +1 more source